Jefferies Boosts Inozyme Pharma with Buy Rating Recognizing Rare Disease Potential
Tuesday, 13 August 2024, 19:28
Jefferies Issues a Buy Rating for Inozyme Pharma
Inozyme Pharma (INZY) stock gained after Jefferies assumed its coverage with a Buy rating, highlighting rare disease opportunities.
Key Highlights
- Jefferies boosts Inozyme with a Buy rating.
- A price target of $17 has been set.
- Emphasis on rare disease growth potential.
Conclusion
This affirmation from Jefferies is expected to enhance investor confidence and interest in Inozyme, stabilizing its stock as the company continues to develop innovative therapies for rare diseases.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.